Table 3.
Treatment overview of the patients according to T2-intensity.
| Pharmacological Treatment | Number (%) | Radiotherapy | Disease control (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total | Iso | Hyper | Total | Iso | Hyper | Total | Iso | Hyper | |
| No treatment | 5 (22.7) | 1 | 4 | 0 | 0 | 0 | 5 | 1 | 4 |
| Oct | 2 (9.1) | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Lan | 5 (22.7) | 3 | 2 | 3 | 2 | 1 | 2 | 1 | 1 |
| Cab | 3 (13.6) | 2 | 1 | 0 | 0 | 0 | 3 | 2 | 1 |
| Oct + Cab | 2 (9.1) | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lan + Cab | 3 (13.6) | 1 | 2 | 1 | 1 | 0 | 3 | 1 | 2 |
| Pas + Cab | 1 (4.5) | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 |
| Peg + Cab | 1 (4.5) | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 |
| Total | 22 (100) | 9 | 13 | 7 | 5 | 2 | 14 (63.7) | 6 | 8 |
Iso: isointense adenomas; Hyper: hyperintense adenomas; Oct: octreotide; Lan: lanreotide; Cab: cabergoline; Peg: pegvisomant.